TransMedics Group Inc (NASDAQ:TMDX)’s stock price shot up 6.9% during mid-day trading on Thursday . The stock traded as high as $25.04 and last traded at $24.85, 176,149 shares changed hands during trading. A decline of 25% from the average session volume of 235,718 shares. The stock had previously closed at $23.25.
Several brokerages recently issued reports on TMDX. Cowen began coverage on Plantronics in a report on Tuesday, May 28th. They set an “outperform” rating and a $67.00 price objective for the company. JPMorgan Chase & Co. began coverage on TransMedics Group in a report on Tuesday, May 28th. They set an “overweight” rating and a $34.00 price objective for the company. Morgan Stanley cut their price objective on Foot Locker from $44.00 to $40.00 and set an “underweight” rating for the company in a report on Tuesday, May 28th. Finally, Canaccord Genuity assumed coverage on TransMedics Group in a report on Tuesday, May 28th. They set a “buy” rating and a $37.00 price objective for the company.
The stock’s fifty day moving average price is $26.68.
TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, June 12th. The company reported ($4.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($4.05). The business had revenue of $4.68 million during the quarter, compared to the consensus estimate of $4.43 million. On average, equities analysts forecast that TransMedics Group Inc will post -1.78 earnings per share for the current fiscal year.
In related news, Director Edwin M. Kania, Jr. bought 33,333 shares of the business’s stock in a transaction on Monday, May 6th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $533,328.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
TransMedics Group Company Profile (NASDAQ:TMDX)
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
